Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Lung Cancer Clinical Trials

Showing 31-35 of 35 items
  • Lung Cancer Mutation Consortium Protocol
  • The primary objective of this protocol is to determine the frequency of oncogenic mutations in 1000 patients with advanced adenocarcinoma of the lung. The linked clinical and mutational analyses will be used to determine the frequency of each mutation, its association with clinical features and outcome, and its association with other mutations. As future therapeutic protocols specific for these mutations are developed, patients may be notified of their eligibility for these studies. Future translational studies may be used to: a) unravel the complex biology of lung cancer; b) identify prognostic markers; c) define predictive markers of response/resistance to new therapies; d) identify new targets. A secondary goal is to establish a consortium of sites that have the capability of conducting multiple mutation testing in a CLIA-certified lab.
  • Diagnoses: Lung Cancer
  • Status: Recruiting
  • A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer
  • This open-label, multicenter study will assess the safety, tolerability, and pharmacokinetics of intravenous (IV) dosing of MPDL3280A and oral dosing of Tarceva (erlotinib) administered in combination to patients with non-small cell lung cancer (NSCLC). This study has two stages. In the safety evaluation stage, patients with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-treatment-naive, advanced NSCLC will be given Tarceva at a starting daily dose of 150 mg for 28 consecutive days during Cycle 1 and for 21-day cycles thereafter. The starting dose of MPDL3280A will be 1200 mg, administered every 3 weeks starting on Day 8 of Cycle 1. If the starting regimen is not tolerated, alternative doses and/or schedules of Tarceva and MPDL3280A may be tested. In the expansion stage, patients with previously untreated, EGFR mutation-positive, advanced NSCLC will be treated with a potential recommended phase 2 dose and schedule based on the treatment established in safety evaluation stage. For both stages, continuation of treatment beyond Cycle 1 will be at the discretion of the treating investigator. In the absence of unacceptable toxicity or disease progression, treatment with MPDL3280A may be continued for a maximum of 17 cycles (or 12 months, whichever occurs first). Tarceva may be continued until disease progression in the absence of unacceptable toxicity. Time on study is expected to be approximately 15 months.
  • Diagnoses: Lung Cancer
  • Status: Recruiting
Showing 31-35 of 35 items
  •   Email
  •   Print
  •   Share
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.


Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters